CN112336756A - Preparation method of acer truncatum leaf tea granules - Google Patents
Preparation method of acer truncatum leaf tea granules Download PDFInfo
- Publication number
- CN112336756A CN112336756A CN201910727611.9A CN201910727611A CN112336756A CN 112336756 A CN112336756 A CN 112336756A CN 201910727611 A CN201910727611 A CN 201910727611A CN 112336756 A CN112336756 A CN 112336756A
- Authority
- CN
- China
- Prior art keywords
- acer truncatum
- preparation
- leaf tea
- extract
- putting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000219226 Acer truncatum Species 0.000 title claims abstract description 59
- 239000008187 granular material Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 241001122767 Theaceae Species 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 15
- 238000001035 drying Methods 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 239000000047 product Substances 0.000 claims abstract description 11
- 239000000706 filtrate Substances 0.000 claims abstract description 10
- 239000006184 cosolvent Substances 0.000 claims abstract description 9
- 238000000605 extraction Methods 0.000 claims abstract description 9
- 239000000796 flavoring agent Substances 0.000 claims abstract description 9
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 9
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 9
- 239000003765 sweetening agent Substances 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000002131 composite material Substances 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 238000000227 grinding Methods 0.000 claims abstract description 5
- 238000010438 heat treatment Methods 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 238000004806 packaging method and process Methods 0.000 claims abstract description 5
- 238000005086 pumping Methods 0.000 claims abstract description 5
- 238000012216 screening Methods 0.000 claims abstract description 5
- 244000269722 Thea sinensis Species 0.000 claims description 33
- 230000000694 effects Effects 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- 229920000858 Cyclodextrin Polymers 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 206010010774 Constipation Diseases 0.000 claims description 5
- 239000001116 FEMA 4028 Substances 0.000 claims description 5
- 229920002774 Maltodextrin Polymers 0.000 claims description 5
- 239000005913 Maltodextrin Substances 0.000 claims description 5
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 5
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 5
- 229960004853 betadex Drugs 0.000 claims description 5
- 229940035034 maltodextrin Drugs 0.000 claims description 5
- 229940013618 stevioside Drugs 0.000 claims description 5
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 5
- 235000019202 steviosides Nutrition 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000004378 Glycyrrhizin Substances 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 229960002737 fructose Drugs 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 235000012907 honey Nutrition 0.000 claims description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 2
- 235000019477 peppermint oil Nutrition 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940085605 saccharin sodium Drugs 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000003908 quality control method Methods 0.000 abstract 1
- 235000013616 tea Nutrition 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000004620 sleep latency Effects 0.000 description 3
- 230000004622 sleep time Effects 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 230000000517 effect on sleep Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 241001143500 Aceraceae Species 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 241000220286 Sedum Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- 229960005256 sulbactam Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/20—Aceraceae (Maple family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method of acer truncatum leaf tea granules, which comprises the following steps: s1, preparing raw materials of acer truncatum leaves, a cosolvent, a flavoring agent and a sweetening agent; s2, putting the acer truncatum leaves into an extraction tank, adding water, heating and decocting, and filtering repeatedly for three times to obtain filtrate; s3, pumping the filtrate into a concentration tank through a liquid pump, and concentrating to obtain an extract; s4, adding auxiliary materials into the extract, and stirring and uniformly mixing in a stirrer; s5, putting the mixture into a dryer, and drying to obtain dry paste powder; s6, putting the dry paste powder into a grinder for grinding, and screening by a vibrating screen; s7, packaging the screened dry paste powder with a medicinal composite film, and bagging to obtain a finished product, which relates to the technical field of traditional Chinese medicine products. The prepared electuary can realize full-ingredient extraction, production science and quality control, and large-scale production can be realized; the granule is convenient for administration, hygiene and storage.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine products, in particular to a preparation method of acer truncatum leaf tea granules.
Background
Acer truncatum, a plant of the genus Acer of the family Aceraceae, is named because the wing fruit is shaped like the gold ingot of ancient China. In the 70 th century of 20 th century, the original professor of the agricultural academy of northwest kingdom of Wang Yang (King's disease) used the acer truncatum seeds for the first time to squeeze edible oil to relieve the tension of edible oil in China, and until 2005, the professor of Wang Yang (Sedum truncatum), discovered that the acer truncatum seeds contain up to 5.2% of nervonic acid, created a new era in brain science history, and discovered that the leaves and seed coats of the acer truncatum also contain a large amount of beneficial bioactive substances through more intensive research. Under the promotion of the scientific research results of the professor of the Wang sex inflammation, a large number of scholars research the acer truncatum from different aspects, such as cultivation and breeding, the content of bioactive substances of each part of the acer truncatum, extraction processes and the like. With the continuous development of the acer truncatum industry, the development and application research of acer truncatum is only carried out on acer truncatum seed oil, and many researchers research the components of acer truncatum leaf active substances, and find that acer truncatum leaves contain various bioactive components such as flavonoids, chlorogenic acid, polysaccharides, vitamins, amino acids, superoxide dismutase (SOD) and the like, wherein the contents of chlorogenic acid and flavonoids are high, and a large amount of research provides a basis for mastering the dynamic content rule of the acer truncatum leaves and the extraction, application and development of the acer truncatum leaves active substances, and provides guidance for accurately and efficiently obtaining and efficiently developing and applying the active components in the acer truncatum leaves in the acer truncatum industry.
Research shows that the acer truncatum bunge leaf has the effects of reducing three highs (hyperglycemia, hyperlipidemia and hypertension), losing weight, helping sleep, resisting oxidation and viruses, enhancing the action of stomach power and the like. Therefore, compared with green tea, the acer truncatum leaf tea is good tea with a health care effect, and has a good development prospect. At present, the acer truncatum leaves are mainly drunk in the form of tea infusion, the decoction quality is difficult to guarantee, the taking is inconvenient, and the storage is difficult. The granule is a product obtained by extracting, concentrating and granulating by modern high and new technology, and ensures the property and taste characteristics of the original raw materials.
Disclosure of Invention
The invention aims to make up the defects of the prior art and provides a preparation method of acer truncatum leaf tea granules, which comprises the following steps:
s1, preparing raw materials of acer truncatum leaves, a cosolvent, a flavoring agent and a sweetening agent;
s2, putting the acer truncatum leaves into an extraction tank, adding water, heating and decocting, and filtering repeatedly for three times to obtain filtrate;
s3, pumping the filtrate into a concentration tank through a liquid pump, and concentrating to obtain an extract;
s4, adding auxiliary materials into the extract, and stirring and uniformly mixing in a stirrer;
s5, putting the mixture into a dryer, and drying to obtain dry paste powder;
s6, putting the dry paste powder into a grinder for grinding, and screening by a vibrating screen;
s7, packaging the screened dry paste powder with a medicinal composite film, and bagging to obtain the finished product.
Preferably, in the S2, water is added, the water is 5-40 times of the acer truncatum leaves, the mixture is heated and decocted for 0.5-5 hours, then the water is added, the mixture is heated and decocted for 0.5-5 hours, and then the water is added, and the mixture is heated and decocted for 0.5-5 hours.
Preferably, in the S3 step, the extract is concentrated to a relative density of 1.00-1.20.
Preferably, in the S4, the auxiliary materials are cosolvent, flavoring agent or sweetener, and the adding amount is 0.05-200%, 0-5% and 0-10% of the extract.
Preferably, the cosolvent comprises one or more of sodium benzoate, citric acid, calcium lactate, maltodextrin, soluble starch and tween 80; the flavoring agent comprises one or more of peppermint oil, essence and beta-cyclodextrin; the sweetener comprises one or more of stevioside, sucrose, honey, fructose, glycyrrhizin, aspartame and saccharin sodium.
Preferably, in the step S5, the temperature of the dryer is 40-100 ℃, and the drying time is 20-100 min.
Preferably, in the S6, the size of the vibrating screen is 80-120 meshes.
Compared with the prior art, the invention has the following beneficial effects: the granule prepared by the invention can realize the extraction of all components, the production science and the quality are controllable, and the large-scale production can be realized; the electuary prepared by the invention is convenient to take, sanitary and convenient to store; the acer truncatum leaf tea granules can effectively shorten the sleep latency of animals, prolong the sleep time and have the effect of promoting sleep; the granule prepared by the invention has the health-care functions of obviously reducing blood fat, blood pressure and blood sugar.
Drawings
The invention is described in further detail below with reference to the following figures and detailed description:
fig. 1 is a schematic view of the present invention as a whole.
Detailed Description
The following description of the embodiments of the present invention is provided for illustrative purposes, and other advantages and effects of the present invention will become apparent to those skilled in the art from the present disclosure.
Please refer to fig. 1. It should be understood that the structures, ratios, sizes, and the like shown in the drawings and described in the specification are only used for matching with the disclosure of the specification, so as to be understood and read by those skilled in the art, and are not used to limit the conditions under which the present invention can be implemented, so that the present invention has no technical significance, and any structural modification, ratio relationship change, or size adjustment should still fall within the scope of the present invention without affecting the efficacy and the achievable purpose of the present invention. In addition, the terms "upper", "lower", "left", "right", "middle" and "one" used in the present specification are for clarity of description, and are not intended to limit the scope of the present invention, and the relative relationship between the terms and the terms is not to be construed as a scope of the present invention.
Example 1: a preparation method of acer truncatum leaf tea granules comprises the following steps:
s1, preparing raw materials of acer truncatum leaves, a cosolvent, a flavoring agent and a sweetening agent;
s2, putting the acer truncatum leaves into an extraction tank, adding water, heating and decocting, and filtering repeatedly for three times to obtain filtrate;
s3, pumping the filtrate into a concentration tank through a liquid pump, and concentrating to obtain 390g of extract;
s4, adding auxiliary materials into the extract, and stirring and uniformly mixing in a stirrer;
s5, putting the mixture into a dryer, and drying to obtain dry paste powder;
s6, putting the dry paste powder into a grinder for grinding, and screening by a vibrating screen;
s7, packaging the screened dry paste powder with a medicinal composite film, and bagging to obtain the finished product.
In the step S2, 1kg of acer truncatum leaves is added with 10L of water, heated and decocted for 1 hour, and the process is repeated for three times.
And in the S3, concentrating the extract until the relative density is 1.07.
And in the step S4, auxiliary materials including maltodextrin, cyclodextrin and stevioside are added, wherein the addition amount of the auxiliary materials is 1%, 1.1% and 2% of the extract.
And in the step S5, the temperature of the dryer is 70 ℃, and the drying time is 30 min.
In the S6, the specification of the vibrating screen is 80 meshes.
Example 2: taking 50g of the acer truncatum leaf extract of the example 1, adding 50g of maltodextrin, 1g of beta-cyclodextrin, 0.5g of stevioside and 500ml of water, stirring for dissolving, and drying in vacuum to obtain a product.
Example 3: taking 50g of the acer truncatum leaf extract of the example 1, adding 50g of soluble starch, 0.5g of beta-cyclodextrin, 1g of cane sugar and 300ml of water, stirring for dissolving, and drying in vacuum to obtain a product.
Example 4: a preparation method of acer truncatum leaf tea granules comprises the following steps:
s1, preparing raw materials of acer truncatum leaves, a cosolvent, a flavoring agent and a sweetening agent;
s2, putting the acer truncatum leaves into an extraction tank, adding water, heating and decocting, and filtering repeatedly for three times to obtain filtrate;
s3, pumping the filtrate into a concentration tank through a liquid pump, and concentrating to obtain an extract;
s4, adding auxiliary materials into the extract, and stirring and uniformly mixing in a stirrer;
s5, putting the mixture into a dryer, and drying to obtain dry paste powder;
s6, putting the dry paste powder into a grinder for grinding, and screening by a vibrating screen;
s7, packaging the screened dry paste powder with a medicinal composite film, and bagging to obtain the finished product.
In the S2, 2kg of fresh acer truncatum leaves are cut into pieces, 20L of water is added, the mixture is boiled for 2 hours, filtered and repeated for three times.
And in the S3, concentrating the extract until the relative density is 1.12.
And in the step S4, auxiliary materials including maltodextrin, cyclodextrin and stevioside are added, wherein the addition amount of the auxiliary materials is 5%, 4% and 8% of the extract.
And in the step S5, the temperature of the dryer is 80 ℃, and the drying time is 45 min.
In the S6, the specification of the vibrating screen is 100 meshes.
Example 5: taking 50g of the acer truncatum leaf extract of the embodiment 4, adding 5g of soluble starch, 0.5g of beta-cyclodextrin, 1g of cane sugar and 200ml of water, stirring for dissolving, and drying in vacuum to obtain a product.
Experimental example 1: experiment of three-high reducing drinking effect
Subject: 200 cases of the patients with hypertension, hyperlipidemia or hyperglycemia are selected as experimental subjects according to clinical test results. Among them, 100 cases are male and 100 cases are female. All ages were between 30 and 55 years, and 200 subjects were randomly divided into 5 groups of 40, of which 20 were male and 20 were female. The judgment standards of hypertension, hyperlipidemia and hyperglycemia are subject to national regulation standards.
The experimental method comprises the following steps: the first, second, third, fourth and fifth groups take the tea granules of the embodiment 1-5 respectively, 2 times a day, 2g each time, and 3 months is a treatment course. During the experiment, other drugs were discontinued. Before the experiment, the special person records the blood pressure, blood fat and blood sugar values of each experimental object, and after three months, the blood pressure, blood fat and blood sugar values of each experimental object are counted again. If any value of the blood pressure, the blood fat or the blood sugar is reduced, the judgment is valid, otherwise, the judgment is invalid.
The results of the experiment are shown in table 1 below:
TABLE 1 Experimental results of drinking effect
Group of | Number of effective persons | High efficiency | Number of invalid persons | Inefficiency of |
First group | 34 | 85% | 6 | 15% |
Second group | 31 | 78% | 9 | 22% |
Third group | 35 | 88% | 5 | 12% |
Fourth group | 34 | 85% | 6 | 15% |
Fifth group | 33 | 83% | 7 | 17% |
And (4) analyzing results: as can be seen from Table 1, the obtained tea granule has the health-care functions of obviously reducing blood fat, blood pressure and blood sugar. Different experimental methods have influence on the effect of the tea granules, probably because different auxiliary materials have influence on the absorption capacity of effective substances in the acer truncatum bunge leaf extract.
Experimental example 2: effect on sleep in mice with threshold dose of sodium pentobarbital
SPF level Kunming mice, male and female, were divided into 3 groups at random according to body weight, each group containing 10 animals, namely model control group, acer truncatum leaf tea granule group (acer truncatum leaf tea granule prepared in example 1), and positive control group (sulbactam). The test substance or 0.5% CMC was administered to each group by gavage for 3 consecutive days 1 time per day. Pentobarbital sodium normal saline solution is injected intraperitoneally at 65mg/kg for 1h after the last administration except for a blank control group. And then observing the turning reflection of the animal, taking the disappearance of the turning reflection for more than 1min as sleep, taking the time of first entering the sleep as a sleep latency, and taking the sleep duration as the sum of multiple times of sleep time. If the user does not go into the sleep or goes into the sleep again within 1h, the test is ended. The results are shown in Table 2.
TABLE 2 Effect on sleep in threshold dose pentobarbital sodium mice
Comparison with model groups: p <0.05, P <0.01
The results show that the mice can enter a sleep state marked by disappearance of the righting reflex after intraperitoneal injection of a threshold dose of sodium pentobarbital.
The experimental result shows that the acer truncatum leaf tea granules can effectively shorten the sleep latency of animals, prolong the sleep time and have the effect of promoting sleep.
Experimental example 3: anti-aging test
The evaluation of the anti-aging effect of the acer truncatum leaf tea granules prepared in the examples 1 to 5 comprises the following specific test methods: 10 volunteers are selected from each experimental group, and the patients with age of 35-55 years have aging phenomena of relaxation, roughness, dullness, wrinkle deepening and increasing and the like; the application method comprises respectively taking the first, second, third, fourth and fifth groups
The tea granules of example 1-example 5 are taken 2 times a day, 2g each time, 1 month is a treatment course, and license plates are filed before and after the experiment. Comparing the photographs of day 0 and 1 month and asking the volunteers for a feeling of use in which facial skin became remarkably tight, elastic, wrinkle-reduced was significant; the facial skin becomes remarkably tight, the elasticity is increased, and wrinkles are reduced; the facial skin was not improved and was not effective. The specific test results are shown in table 3.
TABLE 3 results of the anti-aging test
From the results of table 3, it can be seen that:
the acer truncatum leaf tea granules prepared in the examples 1 to 5 have good anti-aging effect.
Experimental example 4: influence of the tea granules on defecation of constipation model mice
40 Kunming mice are divided into 4 groups according to weight, namely a normal control group (0.5 percent of tragacanth gum), a model control group (0.5 percent of tragacanth gum), a positive control group (rhubarb) and a acer truncatum leaf tea granule group (formula in example 1). Except for the normal control group, the constipation model is reproduced by reserpine and thyroxine after gastric lavage for 7 days; the test suspension was gavaged on day 5, 1 time daily for 3 consecutive days. Mice were placed on filter paper after the last dose and the time to first bowel movement and the number of bowel movements within 5h were recorded and the results are shown in table 4.
TABLE 4 Effect of electuary on defecation of Constipation model mice
Group of | Dosage form | First defecation time(s) | Number of defecation granules (granules) 5h |
Normal control | —— | 14.4±8.5** | 15.7±5.8** |
Model comparison | —— | 110.3±41.2 | 9.2±3.5 |
Positive control (rhubarb) | 0.4g/kg | 32.3±12.1** | 17.2±6.8** |
Acer truncatum leaf tea granule | 0.4g/kg | 52.3±14.6* | 13.1±3.9** |
P <0.05, P <0.01, compared to model control
The experimental results in table 4 show that the acer truncatum tea granules can effectively improve constipation.
Experimental example 5: the tea electuary has the effect of reducing weight
The tea infusion prepared in examples 1-5 was administered to 100kg-125kg of individuals, each of which had 50 trials, 25 men and 25 women. The effect was observed 30 days after 2 times a day with 2g of water. The effects produced after use are shown in table 5.
The experimental results in table 5 show that the acer truncatum leaf tea granules have good weight-losing effect on obese people.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.
Claims (8)
1. The preparation method of the acer truncatum leaf tea granules is characterized by comprising the following steps:
s1, preparing raw materials of acer truncatum leaves, a cosolvent, a flavoring agent and a sweetening agent;
s2, putting the acer truncatum leaves into an extraction tank, adding water, heating and decocting, and filtering repeatedly for three times to obtain filtrate;
s3, pumping the filtrate into a concentration tank through a liquid pump, and concentrating to obtain an extract;
s4, adding auxiliary materials into the extract, and stirring and uniformly mixing in a stirrer;
s5, putting the mixture into a dryer, and drying to obtain dry paste powder;
s6, putting the dry paste powder into a grinder for grinding, and screening by a vibrating screen;
s7, packaging the screened dry paste powder with a medicinal composite film, and bagging to obtain the finished product.
2. The preparation method of the acer truncatum leaf tea granules as claimed in claim 1, which is characterized by comprising the following steps: and in the S2, water is added, the water is 5-40 times of the acer truncatum leaves, the mixture is heated and decocted for 0.5-5 hours, then the water is added, the mixture is heated and decocted for 0.5-5 hours, and the mixture is further heated and decocted for 0.5-5 hours.
3. The preparation method of the acer truncatum leaf tea granules as claimed in claim 1, which is characterized by comprising the following steps: and in the S3, concentrating the extract until the relative density is 1.00-1.20.
4. The preparation method of the acer truncatum leaf tea granules as claimed in claim 1, which is characterized by comprising the following steps: in the S4, the auxiliary materials are cosolvent, flavoring agent or sweetener, and the adding amount is 0.05-200%, 0-5% and 0-10% of the extract.
5. The cosolvent according to claim 4, comprising one or more of sodium benzoate, citric acid, calcium lactate, maltodextrin, soluble starch, and tween 80; the flavoring agent comprises one or more of peppermint oil, essence and beta-cyclodextrin; the sweetener comprises one or more of stevioside, sucrose, honey, fructose, glycyrrhizin, aspartame and saccharin sodium.
6. The preparation method of the acer truncatum leaf tea granules as claimed in claim 1, which is characterized by comprising the following steps: and in the step S5, the temperature of the dryer is 40-100 ℃, and the drying time is 20-100 min.
7. The preparation method of the acer truncatum leaf tea granules as claimed in claim 1, which is characterized by comprising the following steps: in the S6, the specification of the vibrating screen is 80-120 meshes.
8. According to claims 1-8, the tea granule has the effects of reducing high blood pressure, high blood lipid, helping sleep, losing weight, resisting aging and improving constipation.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910727611.9A CN112336756A (en) | 2019-08-07 | 2019-08-07 | Preparation method of acer truncatum leaf tea granules |
PCT/CN2020/080048 WO2021022813A1 (en) | 2019-08-07 | 2020-03-18 | Method for preparing acer truncatum leaf tea granule |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910727611.9A CN112336756A (en) | 2019-08-07 | 2019-08-07 | Preparation method of acer truncatum leaf tea granules |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112336756A true CN112336756A (en) | 2021-02-09 |
Family
ID=74367334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910727611.9A Pending CN112336756A (en) | 2019-08-07 | 2019-08-07 | Preparation method of acer truncatum leaf tea granules |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112336756A (en) |
WO (1) | WO2021022813A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1537628A (en) * | 2003-10-22 | 2004-10-20 | 云南威达元宝枫产业开发有限公司 | Purpleblow maple lozenge for health-care,and its prepn. method |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1227999C (en) * | 2003-10-22 | 2005-11-23 | 云南威达元宝枫产业开发有限公司 | Health-care instant purpleblow maple granule preparaction , and its prepn. method |
CN106804844A (en) * | 2017-01-20 | 2017-06-09 | 谭正杰 | Acer truncatum tea drink formula and preparation method thereof |
CN107439763B (en) * | 2017-09-08 | 2020-11-03 | 无锡新禾创工食品科技有限公司 | Acer truncatum tea beverage and preparation method thereof |
-
2019
- 2019-08-07 CN CN201910727611.9A patent/CN112336756A/en active Pending
-
2020
- 2020-03-18 WO PCT/CN2020/080048 patent/WO2021022813A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1537628A (en) * | 2003-10-22 | 2004-10-20 | 云南威达元宝枫产业开发有限公司 | Purpleblow maple lozenge for health-care,and its prepn. method |
Non-Patent Citations (1)
Title |
---|
汪萌等: "元宝枫的药用植物化学成分及药理作用研究进展", 《黑龙江医药》 * |
Also Published As
Publication number | Publication date |
---|---|
WO2021022813A1 (en) | 2021-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106075130A (en) | A kind of Health-protection traditional Chinese medicinal preparation for fat-eliminating slimming | |
CN101502627B (en) | Chinese medicine health product preparation for preventing and treating alcoholic liver disease and preparation method thereof | |
CN103007146B (en) | Healthcare nutrition powder for enhancing memory ability | |
CN107397208B (en) | Functional food containing fish glue as main component and its use | |
US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
CN105707598A (en) | Plant drink for dispelling alcohol effects and preparation method thereof | |
CN109731066A (en) | A kind of Chinese medicine composition and its application, health food with antifatigue effect | |
CN108813501A (en) | With the relieving cough and reducing sputum health honey paste relievingd asthma and adjust function of human body of clearing heat and moistening lung | |
CN111567797A (en) | Compound jasmine tea chewable tablet and preparation method thereof | |
CN104206586A (en) | Fragrant-type purslane health-caring tea and preparation method thereof | |
CN112336756A (en) | Preparation method of acer truncatum leaf tea granules | |
CN104799292A (en) | Intestine-moistening and bowels-relaxing food and preparation method thereof | |
CN108403933A (en) | A kind of time of childbirth meal is stimulated the secretion of milk qi-blood tonifying Chinese medicine composition of rehabilitation and preparation method thereof | |
CN114651968A (en) | Hangover alleviating composition formula and preparation method thereof | |
CN103652906B (en) | A kind of nourishing Yin and promoting production of body fluid radix rehmanniae recen chewable tablets and preparation method | |
CN107950946B (en) | Instant licorice leisure food and preparation method thereof | |
CN112450396A (en) | Clausena lansium compound composition and preparation method and application thereof | |
CN102485263B (en) | Medicinal composition for treating chronic cough of children and its preparation method | |
CN105535587A (en) | Traditional Chinese medicinal preparation for treating heart and kidney disharmony type palpitation and insomnia and preparation method of traditional Chinese medicinal preparation | |
CN101361767A (en) | Medicine for relieving cough, eliminating sputum, relieving dyspepsia, promoting blood and dissipating blood stasis and preparation method thereof | |
CN108813500A (en) | With tonifying middle-Jiao and Qi, nourishing blood and tranquilization and the health honey paste for adjusting function of human body | |
KR102517826B1 (en) | Manufacturing method of improving composition the health and development of growing children with excellent palatability | |
CN115607629B (en) | Traditional Chinese medicine composition with liver protecting and alcohol effect dispelling functions and preparation method thereof | |
CN102935198B (en) | Food or traditional Chinese medicine for regulating spleen, stomach and intestine functions, sobering up and protecting liver and application of food or traditional Chinese medicine for regulating spleen, stomach and intestine functions, sobering up and protecting liver | |
CN102631486B (en) | Health care composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210209 |